In Mexico, more than 13 million people live with diabetes, while 71 percent of the total population have obesity or are overweight. Morten Vaupel, vice-president and general manager of Novo Nordisk Mexico, details how the Danish company is committed to change and improve diabetes care in partnership with Mexico’s public stakeholders, while also currently expanding its life-changing contribution to the obesity segment.
A growing share of the Mexican population is no longer willing to settle for the treatments available through the public sector and can now afford the most innovative treatments available in the private sector.
